Hansen Medical's Magellan(TM) Robotic System to Be Presented at 40th Annual VEITHsymposium(TM) of Vascular Surgeons and

Hansen Medical's Magellan(TM) Robotic System to Be Presented at 40th Annual 
VEITHsymposium(TM) of Vascular Surgeons and Interventionalists 
MOUNTAIN VIEW, CA -- (Marketwired) -- 11/13/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced it will exhibit its Magellan(TM) Robotic System at the 40th
Annual VEITHsymposium(TM) from November 19th-23rd at the Hilton New
York in New York City. The Company will be conducting product
demonstrations and exhibiting the Magellan Robotic System at Booth
Multiple presentations and physician panel sessions discussing the
growing body of compelling clinical data on the Magellan Robotic
System will also be conducted at the conference. In addition, Hansen
Medical will be co-sponsoring a symposium with Philips Healthcare at
noon on Wednesday, November 20th, titled "Clinical Excellence in the
Hybrid OR." Professor Jean-Pierre Becquemin, M.D. from Henri Mondor
Hospital, Creteil, France will moderate this session and share his
clinical experiences with the Magellan Robotic System in complex
abdominal aortic aneurysm (AAA) repair procedures. Additionally,
Hansen Medical will be the sole sponsor of a symposium at noon on
Thursday, November 21st, titled "Clinical Experiences with the
Magellan Robotic System." Five speakers (Jean Bismuth, M.D.,
Methodist Hospital, Houston; Barry Katzen, M.D., Baptist Cardiac &
Vascular Institute, Miami; Thomas Nolte, M.D., Bad Bevensen in
Germany; Professor Nabil Chakfe, M.D., Hospital Civil Strasbourg in
France; and Professor Nicholas Cheshire, M.D., St. Mary's Hospital,
London) will discuss their clinical experiences with the Magellan
System in a wide variety of endovascular procedure types.  
Hansen Medical also anticipates that the Magellan System will be
featured in the following scheduled presentations:  

--  Summary of Experience with the Hansen Magellan System for Robotic
    Assisted Complex and Routine Endovascular Procedures: Advantages and
    Limitations, by Professor Cheshire; Thursday, November 21st at 2:07
--  Clinical Experience with Vascular Robotics (Hansen) In EVAR, Carotid
    and Other Vascular Applications, by Dr. Katzen; Thursday, November
    21st at 2:12 p.m.

"The VEITHsymposium is one of the year's most important vascular
conferences and we are pleased to have our Magellan System
highlighted prominently in numerous settings throughout the
conference," said Bruce Barclay, President and CEO of Hansen Medical.
"The high level of activity around intravascular robotics at this
meeting is a strong reflection of the continuing momentum we are
seeing both clinically and commercially with the Magellan System
About the Magellan(TM) Robotic System  
Hansen Medical's Magellan Robotic System is intended to be used to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices. The Magellan System is designed to deliver
predictability to simple and complex endovascular procedures. Since
its commercial introduction in the U.S. and Europe, the Magellan
System has demonstrated its clinical versatility in many cases in a
broad variety of peripheral vascular procedure types in centers
across the US and Europe. The system is based upon the flexible
robotic technology incorporated in the Sensei-X(R) Robotic Catheter
System currently sold in the U.S. and Europe, which has been used in
more than 10,000 patients, but includes a number of key enhancements.
In particular, the Magellan Robotic System: 

--  Provides solid catheter stability for placement of therapeutic
--  Is designed to enable predictable procedure times and increased case
--  Allows for independent, individual robotic control of the distal tips
    of both the outer sheath and the inner leader catheter, as well as
    robotic manipulation of standard guidewires.
--  Is designed to allow for sufficient extension inside the body to
    access hard to reach peripheral anatomy.
--  Preserves the open architecture featured in the Sensei System to allow
    for the subsequent use of many 6F therapeutic devices on the market
--  Is designed to potentially reduce physician radiation exposure and
    fatigue by employing a remote physician workstation.

About Hansen Medical, Inc. 
 Hansen Medical, Inc., based in Mountain
View, California, is a global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System, 9Fr
Magellan(TM) Robotic Catheter and related accessories, which are
intended to facilitate navigation to anatomical targets in the
peripheral vasculature and subsequently provide a conduit for manual
placement of therapeutic devices, have undergone both CE marking and
510(k) clearance and are commercially available in the European
Union, and the U.S. In the European Union, the Company's Sensei(R) X
Robotic Catheter System and Artisan(R) and Artisan Extend(R) Control
Catheters are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx(R) Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S., the Company's Sensei X Robotic
Catheter System and Artisan and Artisan Extend Control Catheters are
cleared by the U.S. Food and Drug Administration for manipulation and
control of certain mapping catheters in EP procedures. In the U.S.,
the Sensei X Robotic Catheter System is not approved for use in
guiding ablation procedures; this use remains experimental. The U.S.
product labeling therefore provides that the safety and effectiveness
of the Sensei X Robotic Catheter System and Artisan and Artisan
Extend Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
Forward-Looking Statements
 This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for the
sales cycle for newly introduced products; the rate of adoption of
our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2013 filed with the SEC on
November 8, 2013 and the risks discu
ssed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.  
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contacts: 
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc. 
FTI Consulting, Inc.
Brian Ritchie
John Capodanno
Press spacebar to pause and continue. Press esc to stop.